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60Objective: To investigate the optimum conduit for coronary targets other than the left anterior descending artery,
we evaluated long-term patencies and clinical outcomes of the radial artery, right internal thoracic artery, and
saphenous vein through the Radial Artery Patency and Clinical Outcomes trial.
Methods:As part of a 10-year prospective, randomized, single-center trial, patients undergoing primary coronary
surgery were allocated to the radial artery (n¼ 198) or free right internal thoracic artery (n¼ 196) if aged less than
70 years (group 1), or radial artery (n ¼ 113) or saphenous vein (n ¼ 112) if aged at least 70 years (group 2). All
patients received a left internal thoracic artery to the left anterior descending, and the randomized conduit was
used to graft the second largest target. Protocol-directed angiography has been performed at randomly assigned
intervals, weighted toward the end of the study period. Grafts are defined as failed if there was occlusion, string
sign, or greater than 80% stenosis, independently reported by 3 assessors. Analysis is by intention to treat.
Results: At mean follow up of 5.5 years, protocol angiography has been performed in groups 1 and 2 in 237 and
113 patients, respectively. There are no significant differences within each group in preoperative comorbidity,
age, or urgency. Patencies were similar for either of the 2 conduits in each group (log rank analysis, P ¼ .06
and P ¼ .54, respectively). The differences in estimated 5-year patencies were 6.6% (radial minus right internal
thoracic artery) in group 1 and 2.9% (radial minus saphenous vein graft) in group 2.
Conclusion: At mean 5-year angiography in largely asymptomatic patients, the selection of arterial or venous
conduit for the second graft has not significantly affected patency. This finding offers surgeons, for now, en-
hanced flexibility in planning revascularization. (J Thorac Cardiovasc Surg 2010;139:60-7)Earn CME credits at
http://cme.ctsnetjournals.orgThe long-term durability of revascularization by coronary
artery bypass grafting has been well demonstrated. It stands
in contrast to the demonstrably higher requirements for re-
intervention after percutaneous coronary intervention1,2
and provides the basis on which a patient with coronary
disease may be referred for surgery despite its greater inva-
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The Journal of Thoracic and Cardiovascular SurgeThe Radial Artery Patency and Clinical Outcomes
(RAPCO) trial has been designed to identify the place of
the radial artery (RA) in the hierarchy of conduit options
available to the modern surgeon to supplement the gold stan-
dard left internal thoracic artery (LITA) to left anterior de-
scending (LAD) graft. Patients recruited to this study,
monitored by annual clinical review and angiographic fol-
low-up at defined time points, represent the ideal model in
which to correlate graft patency with their excellent long-
term survival and event-free survival reported previously.3,4
The midterm to long-term graft patencies in this trial may
also further refine our understanding of graft outcomes
with optimized modern secondary medical prevention.PATIENTS AND METHODS
The prospective approval for this trial from the Hospital Committee of
Human Ethics in Research, enrolment criteria, randomization, conduct of
surgery, and clinical or angiographic follow-up patients for the RAPCO
study has been described at length elsewhere.5 In summary, this is a pair
of parallel randomized trials with patients less than 70 years of age random-
ized to receive either an RA or a free right internal thoracic artery (RITA) for
the largest coronary target other than the LAD, and older patients random-
ized to RA or saphenous vein (SV) to a similar target. The target vessel for
the randomized conduit was required to have a diameter of at least 1.5 mm,
with an inflow stenosis exceeding 70% and absence of diffuse distal dis-
ease. It was prospectively selected by review of the preoperative angiogram
and was the largest artery, other than the LAD, meeting the aforementionedry c January 2010
Abbreviations and Acronyms
CI ¼ confidence interval
LAD ¼ left anterior descending coronary artery
LITA ¼ left internal thoracic artery
RA ¼ radial artery
RAPCO ¼ Radial Artery Patency and Clinical
Outcomes
RITA ¼ right internal thoracic artery
SV ¼ saphenous vein
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territory of runoff was used for preoperative or intraoperative final confirma-
tion of the appropriate study target. All patients received a LITA graft to the
LAD, and third- and fourth-order grafts were in accordance with the sur-
geon’s preference. All proximal anastomoses were to be placed to the aorta,
but 4 were anastomosed to other grafts close to the aorta to form Y grafts
with a short common stem when the conduit length of the study graft was
inadequate to reach the aorta comfortably.
A program of postoperative angiography assigned patients to predeter-
mined, randomly allocated intervals varying between 1 month and 10 years
from surgery, weighted toward the second half of the study period. In
addition to their programmed angiogram, all patients were offered a supple-
mentarymidterm angiogram at 5 years. Annual clinical review by a surgeon,
cardiologist, and nurse consultant assigned to the trial, together with
consultation of the National Death Index, were used to gather information
regarding survival and event-free survival. All clinical and angiographic
data were prospectively compiled in a Visual FoxPro 5.0 database (Micro-
soft Corporation, Seattle, Wash) by a dedicated data manager. Preoperative
demographic data were compared by Fisher’s exact test and estimations of
graft patency at time intervals up to 10 years were expressed by generalized
Kaplan–Meier plots and interval censoring. All analyses were verified by
a university statistician using SPSS software (SPSS, Inc, Chicago, Ill).
The analysis of patency was carried out using the intention-to-treat princi-
ple: outcomes were analyzed according to the graft to which the patient was
randomized. The data are interval censored6: all grafts found to be occluded
were discovered in that state at the first protocol-directed angiogram (left
censoring). Patients with patent grafts were taken to be right censored at
the most recent protocol-directed angiogram. Some patients had more
than one protocol-directed angiogram, but no patient in either of the 2
groups had a graft found to be patent at one angiogram and occluded at
the next. Nonparametric methods for interval censored data were used.
The generalized Kaplan–Meier curve was produced using the method of
Turnbull7 and the generalized log–rank test8; the plot was produced inMini-
tab (Minitab Statistical Software; Minitab Inc, State College, Pa) and the
test was carried out in R (R Foundation for Statistical Computing, Vienna,
Austria, using the interval procedure of Fay and Shaw, 2009 [personal
communication]). Importantly, the graph and method used here do not
assume that graft occlusion occurred at any particular time point (eg, the
midpoint) between the operation and the postoperative angiogram. Any
such assumption has potential for misleading results.9RESULTS
The assessment, recruitment, randomization, and follow-
up of patients in the RAPCO trial, in line with the CON-
SORT criteria, are depicted in Figure 1, A and B. Of 1882
patients assessed, 619 were randomized in the RAPCO trial.
Forty patients (29 in group 1 and 11 in group 2) did notThe Journal of Thoracic and Creceive the randomized conduit as an independent graft, pri-
marily owing to lack of conduit of acceptable quality for the
study graft or to a general paucity of conduit availability
requiring use of sequential grafting (which invalidated the
study graft data), owing to surgeon preference, for reasons
that are not clear from the data. Among 29 cases in which
randomization was not followed in group 1, there were 15
crossovers and 14 usages of a non-trial conduit or sequential
technique. In group 2 there were 11 protocol violations, in-
cluding 7 crossovers. All 40 cases are included in the anal-
ysis by intention to treat. Angiographic follow-up has been
performed to date as per randomization of timing of restudy
in all but 2 patients; one was lost to all follow-up and the
other declined angiography. The mean duration of follow-
up was 5.5 years, with a range of 0.1 years to 11.2 years.
The preoperative demographic details of the patients in
the 2 groups in the trial are recorded in Tables 1 and 2.
These detail separately patients whose graft patency has
been assessed to date and the entire randomized cohort
from which they are drawn, for comparison, to confirm
that the group whose protocol angiogram has been per-
formed to date is representative of the whole. The distribu-
tions of age, gender, cardiovascular risk factors, urgency
of surgery, and number of grafts performed are compara-
ble in the 2 arms within each group, except differences
in the proportion of elective surgery in group 2 (66% vs
83%) and in the mean number of grafts per patient (3.1
vs 3.3), which trend toward significance. Other potential
explanatory variables such as peripheral vascular disease
may be important but were not consistently recorded and
are therefore excluded from the analysis. It is noteworthy
that the majority of patients had 3-vessel disease, with the
mean number of grafts 3.0 or greater in all of the 4 arms in
this trial.
The estimated patency of the RA and free RITA in group
1 is depicted in Figure 2. Generalized Kaplan–Meier esti-
mates of graft patency, by intention to treat, in group 1 at
5 years were estimated to be 89.8% in the radial group
(95% confidence interval [CI], 71.0%–100%) and 83.2%
(95% CI, 54.1%–100%) in the RITA group. The absolute
difference between the 5-year patencies (RA minus RITA)
was estimated to be 6.6% (95% CI,28.2% to 41.5%).
There is no demonstrable difference in the patency of each
conduit regardless of analysis by intention to treat (P ¼
.06) or by conduit used, although the numbers at risk beyond
7 years are small. There were 5 and 10 occluded grafts and 5
and 6 string signs in the randomized RA and RITA arms,
respectively. Four of the failed grafts in the group random-
ized to RITA were in fact crossovers. Estimates of patency
in patients who received the correct randomized conduit
show no such trend to difference between RA and RITA
(P ¼ .28).
Similar generalized Kaplan–Meier curves for group 2,
comparing the RAwith SV, are shown in Figure 3. Estimatesardiovascular Surgery c Volume 139, Number 1 61
AB
FIGURE 1. A and B, Recruitment, exclusion, randomization, and follow-up in groups 1 and 2, respectively. RITA, Right internal thoracic artery; LITA, left
internal thoracic artery; AMI, acute myocardial infarction; EF, ejection fraction; BMI, body mass index; FEV1, forced expiratory volume in 1 second.
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were estimated to be 90.0% in the radial group (95% CI,
69.0%–100%) and 87.0% (95% CI, 61.4%–100%) in
the SV group. The difference between the 5-year patencies
(RA minus SV) was estimated to be 2.9% (95% CI,
28.8% to 34.5%). There is, therefore, no demonstrable dif-
ference in the patency estimates of these conduits in patients
aged over 70 years (log–rank, P ¼ .29), regardless of anal-
ysis by intention to treat or by conduit used. Analysis by
conduit used also reveals no difference in patency (P ¼
.40). Inasmuch as there was substantial weighting of the62 The Journal of Thoracic and Cardiovascular Surgetiming of angiography toward the second half of the study
period in this group, the proportion of patients who have un-
dergone restudy at more than 5 years remains small, with
low numbers at risk as a result. To date, 1 SV has a high-
grade in-conduit stenosis and 7 others are occluded. Of the
RAs, 3 are occluded (1 of which is a crossover) and 2
have string sign but none has a stenosis within the conduit.
DISCUSSION
The 5-year (and beyond) patencies in conduits used to
supplement the LITA–LAD graft suggest that the secondry c January 2010
TABLE 1. Preoperative demographic and operative data for group 1 (aged<70 years)
RA restudied by
angiogram (n ¼ 123)
RA enrolled
(n ¼ 198)
RITA restudied by
angiogram (n ¼ 114)
RITA enrolled
(n ¼ 196)
P value (RA restudied vs
RITA restudied)
Age, y (mean and range) 59.6 (42.3–71.0) 59.2 (37.9–71.0) 59.1 (36.2–70.8) 59.5 (36.2–70.9) .96*
Gender (male) 111 (90%) 175 (88%) 109 (95%) 178 (91%) .13y
Diabetes (any) 10 (9%) 22 (11%) 9 (7%) 20 (10%) .96y
Hypertension 64 (51%) 112 (57%) 57 (51%) 99 (51%) .80y
Elective presentation 96 (77%) 160 (81%) 86 (76%) 161 (82%) .65y
Smoking (ever smoked) 92 (73%) 151 (75%) 87 (77%) 137 (70%) .88y
No. of grafts (mean  SD) 3.0  .7 3.1  .8 3.2  .8 3.2  .9 .19*
Distribution of target
vessels for study graft
(Cx: RCA: diagonal (%))
64: 33: 3 62: 35: 3 70: 25: 5 69: 26: 5 .29z
RA, Radial artery; RITA, right internal thoracic artery; SD, standard deviation; Cx, circumflex artery; RCA, right coronary artery. RA restudied versus RA enrolled: P ¼ not sig-
nificant, all variables; RITA restudied versus RITA enrolled: P ¼ not significant, all variables. *t test; yFisher’s exact test; zPearson’s test.
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or free ITA in younger patients and an RA or SV in older
patients, with similar angiographic outcomes. We3,4 have
previously reported clinical outcomes for both groups with
mean 5- or 6-year follow-up, demonstrating equivalent
survival and event-free survival in each group irrespective
of the conduit used. It is gratifying to see that these excellent
clinical outcomes have been matched by high patency rates
beyond 5 years, although it was never presumed that this
would necessarily be so inasmuch as many patients will
survive, even symptom-free, despite graft failures.
The clinical relevance of 5-year patency may lie in pa-
tients whose life expectancy is short. One could argue that
the majority of graft failures might be expected to occur
beyond 5 years and that therefore only the final 10-year
patency results in this study will represent a clinically
important outcome. However, the increasing proportion of
referrals of very elderly patients or of patients with severe
comorbidities such as malignancy, severe pulmonary dis-
ease, or major arteriopathy has led to a growing population
of surgical patients in whom 5-year outcome is all that real-
istically should be considered. Furthermore, it is the comor-
bid conditions in these patients that may in fact define theTABLE 2. Preoperative demographic and operative data for group 2 (age
RA restudied
(n ¼ 53)
RA enrolled
(n ¼ 113)
Age, y (mean and range) 73.4 (61.4–81.5) 72.5 (61.0–83.5)
Gender (male) 44(80%) 91 (81%)
Diabetes (any) 16 (29%) 50 (44%)
Hypertension 23 (47%) 67 (59%)
Elective presentation 35 (71%) 87 (77%)
Smoking (ever smoked) 37 (73%) 75 (66%)
No. of grafts (mean  SD) 3.1  .8 3.2  .9
Distribution of target
vessels for study graft
(Cx: RCA: diagonal (%)
73: 25: 2 70: 25:
RA, Radial artery; SV, saphenous vein; SD, standard deviation; Cx, circumflex artery; RCA
The Journal of Thoracic and Cusability of conduits. The finding of comparable patencies
in both groups, together with previously reported equal clin-
ical outcomes, allows the surgeon freedom to match the
choice of conduit to the patient’s other conditions, with
the evidence suggesting that this selection will not compro-
mise the midterm success of the coronary operation. Clearly,
for younger or fitter patients whose life expectancy is antic-
ipated to be a decade or more, full 10-year patency and clin-
ical outcome data from this trial will be essential before the
optimum revascularization strategy can be defined.
We3 have discussed elsewhere that the free RITA was
included in this trial for 2 reasons. First, we did not wish
to compromise the use of the gold standard LITA–LAD
graft and an in situ RITA could not reach all targets.
Second, RAPCO was designed as a biological comparison
of different conduits used in a similar manner; thus the
RITA was used as a free graft as the RA or SV would
be. Subsequently, however, we have been persuaded of
the benefits of bilateral in situ ITA grafting10,11; nonethe-
less the finding of excellent angiographic and clinical
outcomes with the free graft adds an extra layer of flexibil-
ity in view of its capacity to reach a wider spectrum of
targets than an in situ graft.d>70 years)
SV restudied
(n ¼ 60)
SV enrolled
(n ¼ 112)
P value (RA restudied vs
SV restudied)
72.9 (60.5–80.6) 73.1 (60.5–80.7) .59*
51 (86%) 91 (81%) .80y
23 (39%) 52 (46%) .43y
37 (61%) 77 (69%) .06y
50 (81%) 91 (81%) .05y
42 (71%) 76 (68%) .98y
3.3  .7 3.3  .7 .05*
58: 37: 60: 37: 2 .31z
, right coronary artery. *t test; yFisher’s exact test; zPearson’s test.
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FIGURE 2. Kaplan–Meier estimates of graft patency in group 1 by inten-
tion to treat. RA, Radial artery; RITA, right internal thoracic artery.
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FIGURE 3. Kaplan–Meier estimates of graft patency in group 2 by inten-
tion to treat. RA, Radial artery; SV, saphenous vein.
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DA striking finding is the patency of SV grafts beyond 5
years, which exceeds that described in historical series.12-14
It seems likely that rigorous application of secondary pre-
vention methods and modification of lifestyle factors has
had a powerful effect on patency of vein grafts over the
past 20 years. Surgically, an enhanced understanding of
the importance of careful conduit handling, avoidance of
overdistention, and discarding of any segments of RA or
vein of modest quality may have led to an improvement in
the technical conduct of procedures using arterial and ve-
nous grafts. If a controlled elective setting may favor supe-
rior surgical results compared with urgent surgery in an
unstable patient, this discrepancy may have narrowed any
potential difference between the patency of arterial versus
vein grafts, but this does not affect the discrepancy between
current and historical reports of vein graft patency. From the
optional angiograms, we15 previously reported patency of
SV grafts of 82.4% at 5 years, but this included vein grafts
performed to second-, third- and fourth-order coronary
targets, with a reduction in the mean patency owing to inclu-
sion of smaller caliber coronary vessels or smaller territory
of runoff in lesser targets. When the SV is used only to the
second best target, patency is better (90% at 5 years on op-
tional angiograms,15 80% at 9 years in the protocol directed
angiograms presented above).
The most appropriate method of analysis in this study of
angiographic patency is, and has been, a source of debate.
Standard conduct in a randomized trial is to analyze by
intention to treat, and we have followed this convention,
acknowledging that analysis by conduit used rather than
assigned compromises the principles of randomization as
a means of removing bias. However, in group 1 there
were 9 grafts randomized to RITA that instead received64 The Journal of Thoracic and Cardiovascular Surgean RA, 4 of which failed. This 44% failure rate among
crossovers in group 1 favors the RA over the RITA be-
cause intention-to-treat principles allocates the 4 failures
to the RITA cohort. The described absolute difference in
patency in group 1 (6.6%) disappears if intention to treat
is not used.
CONCLUSIONS
Comparable angiographic and clinical outcomes at mean
5- to 6-year follow-up can be achieved with any free arterial
graft in patients aged less than 70 years, and with an RA or
SV in older patients, when grafted to the largest non-LAD
target. This finding allows the surgeon considerable flexibil-
ity in the selection of conduits according to other patient co-
morbidities or factors, when 5-year outcome is envisaged.
Whether the free arterial grafts are equivalent or superior
to SV grafts in younger patients is not known, and caution
should be expressed in extrapolation of patency results
from second-order coronary targets to lesser targets,
although the likely clinical impact of graft failure in the
territories of lesser targets diminishes accordingly. Graft
patencies of all conduits beyond 5 years are excellent and
are superior to those reported in historical controls. We
have previously reported excellent survival and event-free
survival in participants enrolled into our randomized con-
trolled trial: confirmation of graft patency in these patients
underpins clinical outcomes and reassures patient, cardiolo-
gist, and surgeon alike.
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Dr Stephen E. Fremes (Toronto, Ontario, Canada). I do not
have any personal conflicts of interest to declare.
This study reports on a 5-year patency of RA, free RITA, and SV
grafts to non-LAD targets. The study is remarkable in that more
than 600 patients were recruited for a surgical trial, all from a single
center. The study has been performed with great rigor, with few
protocol violations or crossovers, with excellent follow-up, and
with a high rate of late angiography. Putting this study into context,
the study comes from a center with a long history in angiographic
and clinical outcomes of coronary surgery, as well as the influence
of arterial conduits on patency.
Again, this study is, in reality, two separate trials, one comparing
the free RITA with the RA in younger patients and the second com-
paring RAs with the SV in older patients. The former study is truly
unique and to my knowledge is the first and only randomized con-
trolled trial comparing a free RITA and an RA. I would like to em-The Journal of Thoracic and Cphasize, however, that the authors are reporting 5-year results, and
it should be emphasized again that according to protocol, the angio-
graphic follow-up of the study is weighted toward the sixth to tenth
postoperative years. I have a few questions.
First, the manuscript says that the primary analysis was per-
formed according to a treatment received rather than an intention-
to-treat basis. Why would you do that when it is more likely
to introduce bias in terms of your results?
Dr Hayward. Thank you for your question, Dr Fremes. We had
a lot of discussions about whether the analysis should be by inten-
tion to treat. We reported last year the clinical outcome data, which,
as in any clinical trial, were analyzed by intention to treat, and we
therefore initially thought that we should follow that and report the
patency by intention to treat. However, it seemed a little curious to
report the patency of what we know to be an SV to a given target,
for example, as if it were an RA, as intended. The conduit is known,
the target is known, and if the crossover was for a legitimate reason,
its patency is a fact, related presumably to the conduit used, what-
ever was planned. The trial is intended as a pragmatic trial to guide
surgeons. The surgeon wants to know, ‘‘If I place a saphenous vein
to this marginal, what will the patency be?’’, rather than ‘‘What
would the patency be if I planned to perform a radial, but didn’t?’’
So after some discussion we decided to follow the conduit used.
However, I agree that you can argue it either way. We did in fact
perform the analysis by intention to treat as well just for a statistical
cross-check, and actually it does not influence the results one iota.
But I agree that you could make this criticism of our decision.
Dr Fremes. I think if there are a lot of crossovers, then it is very
difficult to know what to do, but you had very few crossovers or
protocol violations.
Have you identified any patient or vessel predictors of graft fail-
ure overall or for the different types of grafts?
Dr Hayward. In this subset, no, we have not, because we have
not asked the question.We decided that because the number of graft
failures thus far has been relatively small, we would be playing with
such small numbers that it would be meaningless. Thus we have not
yet done the sort of analysis that you published for your cohort last
year. That will come when we have the full 10-year data.
Dr Fremes. I suspect that several patients have likely undergone
serial angiography in your study. Do you have any insights that
may be relevant from these patients?
Dr Hayward. From an article we published last year, we did re-
port a small number of patients that have had serial angiograms.
They were patients who had the protocol-directed angiogram and
then opted for the 5-year angiogram as well, and there were only
two changes, or two failures, in cases that had previously been re-
ported. Therefore, there was a 99% correlation. The groups that I
have just presented today contain only the protocol-directed angio-
grams. We took the last angiogram as the end point, effectively.
The moment a graft failed, it remains failed whatever a future an-
giogram may suggest, or if for some reason they had two angio-
grams and both have shown the graft as patent, we have taken
the longer follow-up, for obvious reasons.
Dr Fremes. That is fine for the results, but were there any se-
quential findings that may give you some insights as to what might
happen if there is longer-term follow-up?
DrHayward.Not yet at this point, no. Not enough patients have
had two angiograms.ardiovascular Surgery c Volume 139, Number 1 65
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SV. The patients were recruited largely from the 1990s as opposed
to somemore recent studies, for example, the PREVENT IV, which
have shown much poorer results. Can you speculate as to the pos-
sible reasons for this disparity?
Dr Hayward. I think ultimately the two factors have been sur-
gical technique and secondary prevention. I think secondary pre-
vention has been absolutely rigorous in that all patients have
been monitored by their hospital cardiologist, and the standard of
practice is extremely high in Australia. I agree that some of the pa-
tients were operated on at a time before with what we might regard
as the latest preventative strategies, but all the patients received ap-
propriate medications from surgery onward.
More important, though, is the surgical technique. The rigor with
which high-quality conduit is selected in Melbourne is very signif-
icant, in my opinion, and the delicacy and respect with which it is
handled is also striking. Because there is such concern about the
quality, often large amounts of conduit are harvested and only
a smaller segment used. I think it is that selectivity that has made
the difference here.
Dr Fremes. I have one final question, and you have alluded to
this a bit already: were there clinical events attributable to study
graft failure and how did they compare between the different grafts?
Dr Hayward. We do know the clinical events and published
these last year, and we do know the patients with the study graft
failures. In the 10-year results we are going to correlate those
two. But in the current patency data we did not attempt to link
the patients from the two presentations, because at the moment
there have only been clinical events in about 10% of patients,
and there are only a small number of failed grafts. Thus there really
are not enough to draw any conclusions at this time. I have delib-
erately not done that. The data are there, but I think we should
wait until we have more graft failures.
Dr Thomas Z. Lajos (Greenwood, SC). I have no conflicts of
interest. I would like to congratulate the authors for this very excel-
lent study. I would like to make a comment and a question.
We investigated veins, reverse veins, with valves and without
valves, 10 years ago, and we found that if you take the best quality
veins on both sides, the longer patency is present in those that have
no valves. So it is a valveless vein. Their patency is about the same
as you have shown, and we found the same thing; with the veins,
when the follow-up starts to decrease, patency is in the end of 9
to 10 years. The valves in the veins create a dilatation, they create
turbulence, and they may create emboli and thrombus inside. Did
you discard those veins or you did you have a chance to discard
those veins that had valves versus no valves?
Dr Hayward. Veins were not necessarily discarded per se be-
cause they had valves, but because of the practice of selecting the
very best conduit. Where possible, lengths are trimmed between
the valves. So as far as possible we would have valveless segments
of vein. That, of course, is not achievable in all patients. But I agree
that no doubt the turbulence at those points is a major factor. Some-
times dilatations or outpouchings can be flattened off with a large
clip to try to make a smoother profile, but that does not remove
the disturbance of flow imposed by a valve. I would say that valves
are avoided where possible, but I would not say that this is a series
of valveless veins. That would be misleading. However, I certainly
agree with your conclusions.66 The Journal of Thoracic and Cardiovascular SurgeDr Georg Lutter (Kiel, Germany). Congratulations for your
good patency rate of your RA. Can you give us a little insight of
whether you applied some vasodilating substances to your RAs?
A second question might be whether you dissected them. Did
you take the fascia, the small thin layer of the fascia off, or did
you leave the conduit in place as you took it out from the lower
arm?
DrHayward. The RAs in our unit and by other surgeons inMel-
bourne are harvested by a very standardized technique that the se-
nior surgeons locally developed. One of the important design
features of the trial was that they standardized everything that
they could with the conduits. The RA is taken as a pedicle, a rela-
tively narrow pedicle, but the artery is never touched at all, and the
only manipulation is of the fascia. The artery is divided early on dis-
tally and then retrogradely injected with a solution of papaverine
dilated in blood and Ringer lactate 50/50, and that same solution
is used for the veins as well. The graft is then clipped off at the distal
end and the dissection of the pedicle is then completed while the
graft is allowed to dilate with normal blood pressure; only at the
last minute is it removed from the proximal end. Then it is placed
in a bath of papaverine and blood and Ringer lactate. All the con-
duit types were treated in the same manner.
Dr Thoralf Sundt (Rochester, Minn). I suspect I know the an-
swer to this question, but there has been speculation that the poor
vein graft patency in the PREVENT IV trial was due to endoscopic
harvest. Were any of these veins harvested endoscopically, and
could you make a comment about the potential impact of that inno-
vation on graft patency?
DrHayward.All the veins were harvested by an open technique
here. I think that the delicacy with which the conduit is handled in
Melbourne would make an endoscopic approach to this very diffi-
cult. Many of us who have had any experience, and in my case rel-
atively limited experience, with endoscopic harvest have been
uncomfortable with the amount of traction I or we have placed
on the vessels. Endothelial integrity is absolutely key to these pa-
tency results, and this integrity might have been threatened by an
endoscopic method. These veins were all taken in a shamelessly
open no-touch manner.
DrCharles C. Canver (Riyadh, Saudi Arabia).Congratulations
on your outstanding work. I think you, Dr Buxton, and your other
group members have contributed immensely to our understanding
of the clinical use of the RA as a conduit. Most of the experienced
surgeons sensed the need for the RA during coronary artery bypass
grafting, but most were very skeptical owing to its vasospastic na-
ture. Accordingly, it is gratifying to see that your results support
that the RA is probably the second best arterial conduit. I have
a couple of questions for you.
First, have you ever used the RA as a sequential graft or have you
simply used the RA to a single coronary target? Second, if the pa-
tients had insulin-dependent diabetes, did you validate the quality
of the in situ RA? Last, have you used any preservative solutions
to prevent RA spasm just before its use in the operating room,
that is, a mixture of papaverine, nitroglycerin, diltiazem, or what-
ever? In addition, did you use any perioperative intravenous vaso-
dilators, that is, diltiazem, nitroglycerin, or milrinone?
Dr Hayward. Thank you. I will take your questions in reverse
order. On the table, as I said, after harvesting, the conduit is in a pa-
paverine–blood–Ringer lactate bath and is kept flushed with thisry c January 2010
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Dsolution. In terms of intravenous agents, at completion of the pro-
cedure the patients at Austin are given low-dose milnirone as an ar-
terial graft dilator, and that is run for about 24 hours unless there is
a reason to discontinue it, such as low systemic vascular resistance
state or excessive cardiac output. The use and dose of the milnirone
is entirely vasodilating in its intent rather than inotropic. I think that
is an important factor in the treatment of arterial grafts in this series.
A substantial number of the patients did have diabetes. Type II
diabetes was predominant, although type I diabetes was present
in about 15% of those with diabetes. The patients were all assessed
by a preoperative Allen test, and then intraoperatively, before use,
the RA was inspected and palpated for calcification. After harvest-
ing, if the internal lumen showed evidence of atheroma or calcifica-
tion, then it was discarded. There was no Doppler study, if that isThe Journal of Thoracic and Cwhat you were referring to, but a fairly rigorous visual inspection
and palpation were made of the conduit.
Your final question had to do with sequential grafts. All of these
are grafts with single distal anastomoses. There were a few patients
who received sequential grafts, but they were then eliminated from
the study, as shown on the flow diagram. We are not opposed to se-
quential grafting, and in fact, a proportion of the LITAs were se-
quentially grafted. I think there is a growing body of opinion that
if you double the territory of runoff for the graft, you may in fact
improve its patency, but that could bias your patency data. For
the purposes of this trial, to keep it simple and reproducible, the ran-
domized or study conduit had to be used with one distal end, and if
used sequentially with a larger bed of runoff, it was eliminated from
the study.ardiovascular Surgery c Volume 139, Number 1 67
